

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
13 January 2011 (13.01.2011)

(10) International Publication Number
WO 2011/004162 A3

PCT

(51) International Patent Classification:

C07D 285/08 (2006.01) **C07D 417/12** (2006.01)
C07D 417/10 (2006.01) **A61K 31/433** (2006.01)

(21) International Application Number:

PCT/GB2010/001315

(22) International Filing Date:

8 July 2010 (08.07.2010)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/213,735 8 July 2009 (08.07.2009) US

(71) Applicant (for all designated States except US): **BE-TAGENON AB** [SE/SE]; Box 2339, S-103 18 Stockholm (SE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **WESTMAN, Jacob** [SE/SE]; Medchemcon AB, Blomsberg, S-740 21 Järlåsa (SE). **HALLETT, Allan** [GB/GB]; Antisoma Research Limited, BioPark Hertfordshire, Broadwater Road, Welwyn Garden City, Hertfordshire AL7 3AX (GB). **VAGBERG, Jan** [SE/SE]; Brantstigen 8, S-192 54 Solentuna (SE).

(74) Agent: **MCNEENEY, Stephen**; Potter Clarkson LLP, Park View House, 58 The Ropewalk, Nottingham NG1 5DD (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(88) Date of publication of the international search report:

3 March 2011

(54) Title: 1, 2, 4-THIAZOLIDIN-3-ONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER

(57) Abstract: According to the invention there is provided a compound of formula (I) wherein: A represents C(=N-W-D) or S; B represents S or C(-NH-W-D); when: A represents C(=N-W-D) and B represents S then the bond between B and the NH atom is a single bond; or A represents S and B represents C(-NH-W-D) then the bond between B and the NH atom is a double bond; X represents -Q-[CR^xR^y]_n-; W represents -[CR^xR^y]_m- or -C(O)-[CR^xR^y]_p-; Q represents a bond, -N(R^a)-, -S-, or -O-; A₁ to A₅ respectively represent C(R¹), C(R²), C(R³), C(R⁴) and C(R⁵), or, alternatively, up to two of A₁ to A₅ may independently represent N; D represents phenyl, pyridyl or pyrimidinyl optionally substituted by one or more R⁶ groups, which compounds are useful in the treatment of cancer.



WO 2011/004162 A3